Ranking of the top ten global pharmaceutical companies in R&D investment in 2020: Roche ranked first, BMS achieved a "triple jump", Eli Lilly returned to TOP10, AZ fell out of the top ten

Among them, Roche ranks first in the world with 13 billion Swiss francs (about 13.

(Source: Fierce Biotech)

R&D investment: 13 billion Swiss francs (about 13.

Compared with 2019: an increase of 1.

Total revenue in 2020: 58.

R&D investment as a percentage of total revenue: 22.

R&D investment: 13.

Compared with 2019: an increase of 3.

Total revenue in 2020: 48 billion US dollars (about 314.

R&D investment as a percentage of total revenue: 28.
3%

Merck’s investment in research and development rose from third in 2019 to second in 2020, replacing Johnson & Johnson.
Although it has spent a "big price" on the research and development of the new crown vaccine, Merck has not received the corresponding "profit.
" Compared with Roche's money spent on testing for the new crown virus, Merck's investment in the new crown epidemic seems "a little misguided.
"

NO.
3: Johnson & Johnson (Johnson & Johnson)

Research and development investment: 12.
15 billion US dollars (approximately 79.
57 billion yuan)

Compared with 2019: an increase of 790 million US dollars (about 5.
17 billion yuan)

Total revenue in 2020: US$ 82.
6 billion (approximately 541 billion yuan)

R&D investment as a percentage of total revenue: 14.
7%

In the same study of the new crown vaccine, Johnson & Johnson's results are better than that of Merck.
Part of Johnson & Johnson's research and development expenses in 2020 will also be used for the development of the new crown vaccine.
In addition, Johnson & Johnson has also made a "heavy injection" in the field of tumors and autoimmune diseases.

NO.
4: Bristol Myers Squibb (BristolMyers Squibb)

R&D investment: 11.
14 billion US dollars (about 72.
96 billion yuan)

Compared with 2019: an increase of 5 billion US dollars (about 32.
74 billion yuan)

Total revenue in 2020: US$42.
5 billion (approximately 278.
36 billion yuan)

R&D investment as a percentage of total revenue: 26%

In 2019, Bristol-Myers Squibb spent US$74 billion to acquire Celgene and acquired an important asset, the CAR-T therapy Breyanzi.
The company will naturally make a lot of investment in CAR-T therapy in 2020, and these investment will soon be transformed into products.
In February 2021, Breyanzi was approved by the FDA for marketing, becoming the fourth CAR-T therapy in the world.
In addition, Bristol-Myers Squibb has also invested in autoimmune diseases.

NO.
5: Pfizer

R&D investment: US$9.
4 billion (about 61.
56 billion yuan)

Compared with 2019: an increase of 750 million US dollars (approximately 4.
91 billion yuan)

Total revenue in 2020: US$41.
9 billion (approximately 274.
43 billion yuan)

R&D investment as a percentage of total revenue: 22.
4%

Although Pfizer's ranking in terms of R&D investment in 2020 is the same as that in 2019, both ranked fifth, Pfizer's performance in the new crown vaccine during the epidemic was particularly outstanding.
In addition to gains in the new crown vaccine, Pfizer also said that it has also achieved good results in the success rate of research and development, and the proportion of successfully entering phase II clinical trials has increased from 15% a few years ago to 50% now.
In addition to the new crown vaccine, Pfizer has also invested in infectious diseases and antibiotics.

NO.
6: Novartis

R&D investment: 8.
9 billion US dollars (approximately 58.
29 billion yuan)

Compared with 2019: a decrease of 500 million U.
S.
dollars (approximately 3.
27 billion U.
S.
dollars)

Total revenue in 2020: 48.
65 billion US dollars (about 318.
64 billion yuan)

R&D investment as a percentage of total revenue: 18.
2%

Compared with the continuous investment of the top five companies in R&D, Novartis’s investment in 2020 is about 500 million US dollars less than in 2019, and the proportion of R&D in total revenue has also dropped from 19.
8% in 2019 to 18.
2% in 2020.
.
The reason for the reduction in its research and development costs is also related to the new crown virus.
When other companies added new crown virus tests or vaccines, Novartis did not invest much in these areas.
In addition, because of the new crown epidemic, Novartis's clinical trials have been postponed, which has reduced R&D investment to a certain extent.

NO.
7: GlaxoSmithKline

Research and development investment: 5.
52 billion pounds (about 7.
7 billion US dollars, about 50.
43 billion yuan)

Compared with 2019: an increase of 950 million pounds (about 1.
3 billion US dollars, about 8.
51 billion yuan)

Total revenue in 2020: 34.
09 billion pounds (about 47.
51 billion US dollars, about 311.
17 billion yuan)

R&D investment as a percentage of total revenue: 16.
1%

As one of the world's largest manufacturers of vaccine drugs, GlaxoSmithKline naturally joined the research and development ranks of the new crown vaccine, but the result was similar to that of Merck, both of which were "broken" on the beach.
In addition to increasing research and development costs for the new crown vaccine, GlaxoSmithKline also invests in research and development in tumors, digestive diseases, and cell therapy.

NO.
8: Sanofi

R&D investment: 5.
52 billion euros (about 6.
51 billion US dollars, about 42.
68 billion yuan)

Compared with 2019: a decrease of 500 million euros (about 590 million US dollars, about 3.
86 billion yuan)

Total revenue in 2020: 36 billion euros (approximately 42.
6 billion US dollars, approximately 278.
37 billion yuan)

R&D investment as a percentage of total revenue: 15.
3%

In terms of R&D investment, Sanofi and Novartis both reduced US$5.
6 billion, but the reasons for Sanofi's cost reduction are not the same as Novartis.
Under the leadership of the newly appointed CEO Paul Hudson, Sanofi cut the mess quickly and abandoned the company's weakest R&D projects and departments.
The money saved is invested by Sanofi in tumors, rare diseases and other areas that can bring "growth power".

NO.
9: AbbVie

R&D investment: US$6.
55 billion (approximately 42.
9 billion yuan)

Compared with 2019: an increase of 150 million US dollars (about 980 million yuan)

Total revenue in 2020: 45.
8 billion US dollars (approximately 299.
97 billion yuan)

R&D investment as a percentage of total revenue: 14.
3%

AbbVie’s R&D investment in 2020 has increased by US$150 million compared to 2019, but the amount is not much.
In 2020, AbbVie's R&D investment is mainly in the treatment of new coronaviruses, tumors and cell therapies.

NO.
10: Eli Lilly

R&D investment: 6.
08 billion US dollars (approximately 39.
82 billion yuan)

Compared with 2019: an increase of 480 million US dollars (about 3.
14 billion yuan)

Total revenue in 2020: US$24.
5 billion (approximately 160.
46 billion yuan)

R&D investment as a percentage of total revenue: 24.
8%

Although Eli Lilly’s R&D investment in 2020 is the least among the 10 companies, compared to 2019, its R&D investment has increased by 9%.
Similarly, Eli Lilly has also increased its investment in new coronavirus treatment drugs.
In addition, Eli Lilly has also increased its investment in gene therapy and diabetes drugs.